Current Report · Items 5.02 · 8-K

Gain Therapeutics, Inc.

GANXNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Sep 28, 2026Accepted Sep 28, 2026, 4:30 PM EDTCIK 1819411Accession 0001104659-26-111391

Company context

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, rexaceract is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Current securities

GANXNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Gain Therapeutics, Inc. · 8-K · Filed 2026-09-28

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value

Symbol: GANX
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-09-22

Dimensions: Not supplied

Accession 000110465926111391 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Principal Financial Officer On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from his positions with the Company, with such resignation to be effective September 30, 2026, in order to pursue other opportunities. Appointment of Interim Chief Financial Officer On September 24, 2026, the Company’s board of directors appointed Gene Mack, the Company’s current President and Chief Executive Officer, to serve as the Company’s interim Chief Financial Officer, effective as of October 1, 2026. In connection with this appointment, Mr. Mack will continue in his roles as President and Chief Executive Officer and will assume the duties of the Company’s principal financial officer and principal accounting officer until his successor is appointed or until his earlier resignation or removal, and until such time as a permanent replacement is named. The Company is engaged in an ongoing search for a permanent replacement to serve as its principal financial officer and principal accounting officer. Mr. Mack’s biographical information is set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 26, 2026, and is incorporated by reference herein. The compensatory and other material terms of Mr. Mack’s employment with the Company will remain unchanged in connection with the foregoing. There are no arrangements or understandings between Mr. Mack and any other persons pursuant to which Mr. Mack was selected as the Company’s interim Chief Financial Officer. Mr. Mack does not have any family relationship with any of the Company’s other directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. Mr. Mack does not have any direct or indirect interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.